OTC:NUMD
Nu-Med Plus, Inc.
A financially distressed OTC biotech entity reporting zero revenue and massive annual losses with a negative shareholder equity position.
Key Metrics
Investment Thesis
Bull Case
Speculative investors might view NUMD as a turnaround opportunity if management can successfully pivot to a viable business model or secure emergency financing. Any future product approvals or partnerships could theoretically lead to exponential growth from current zero revenue levels. The low share price and high volatility offer potential for short-term capital gains based on news-driven catalysts.
Bear Case
The stock is fundamentally broken with no revenue stream, massive annual losses of $68.3 million, and negative equity that precludes sustainable operations. Current liabilities are nearly 24 times greater than current assets, indicating a high probability of default or forced liquidation. There is no earnings growth trajectory to support the valuation, making it an extremely poor investment for risk-averse capital.
About Nu-Med Plus, Inc.
Nu-Med Plus, Inc. (NUMD) is a micro-cap biotechnology firm operating on the OTC market with no reported revenue or gross profit in recent years. The company faces significant liquidity challenges evidenced by a net loss of $68.3 million and a substantial retained earnings deficit of nearly $10 million. With total liabilities exceeding assets at $224.5 million versus $9.4 million, the firm relies on non-operating income sources rather than product sales.
Analysis
Management Discussion
Management has failed to generate any operating profit, resulting in a net loss of $68.3 million driven by general and administrative expenses of $34.3 million and other operating expenses of $29.0 million. Cash flow from operations was negative at -$4.4 million, further depleting the already low cash and equivalents balance of $2.4 million. The absence of revenue for five consecutive years highlights a critical failure to commercialize products or services.
Industry Overview
The biotechnology and pharmaceutical industry requires substantial capital expenditure and time to develop products before generating revenue. Companies in this sector often face high failure rates during clinical trials, but those that succeed can achieve monopoly-like pricing power once patents are secured. However, the current financial state of NUMD suggests it has not yet navigated the capital-intensive development phase successfully.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 |
| Operating Expenses | $182.2K | $120.5K | $63.3K |
| Operating Income | $-182.2K | $-120.5K | $-63.3K |
| G&A | $26.6K | $27.6K | $34.3K |
| Stock-Based Comp | $35.0K | $41.8K | — |
| D&A | $2.3K | — | — |
| Depreciation | $2.3K | — | $0 |
| Other OpEx | $155.6K | $93.0K | $29.0K |
| Non-Operating Income | $52.0K | $-5.0K | $-5.0K |
| Interest Expense | $1.0K | — | — |
| Pre-Tax Income | $-130.2K | $-125.5K | $-68.3K |
| Income Tax | $0 | $0 | $0 |
| Continuing Ops | $-130.2K | $-125.5K | $-68.3K |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-130.2K | $-125.5K | $-68.3K |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-130.2K | $-125.5K | $-68.3K |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $79.5K | $13.5K | $9.4K |
| Cash & Equivalents | — | — | $2.4K |
| Other Current Assets | — | — | $7.0K |
| Long-Term Assets | $0 | $0 | $0 |
| Total Assets | $79.5K | $13.5K | $9.4K |
| Current Liabilities | $142.6K | $160.2K | $224.5K |
| Accounts Payable | $7.2K | $8.1K | $43.0K |
| Other Current Liab | $134.4K | $146.1K | $166.7K |
| Long-Term Liabilities | $0 | $0 | $0 |
| Total Liabilities | $142.6K | $160.2K | $224.5K |
| Shareholders' Equity | $-63.0K | $-146.8K | $-215.1K |
| Paid-In Capital | $9.6M | $9.6M | $9.6M |
| Retained Earnings | $-9.7M | $-9.8M | $-9.9M |
| Total L&E | $79.5K | $13.5K | $9.4K |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-130.2K | $-125.5K | $-68.3K |
| Non-Cash Adjustments | $-17.2K | $41.2K | $-700 |
| Working Capital Changes | $108.9K | $17.9K | $64.6K |
| Cash from Operations | $-38.5K | $-66.4K | $-4.4K |
| Cash from Investing | $0 | — | — |
| Cash from Financing | $100.0K | — | — |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $61.5K | $-66.4K | $-4.4K |
| Beginning Cash | $11.7K | $73.2K | $6.8K |
| Ending Cash | $73.2K | $6.8K | $2.4K |
Frequently Asked Questions
How does Nu-Med Plus, Inc. make money?
The company reports no revenue from continuing operations, indicating a lack of active commercial business segments or successful product launches. Financial data suggests the entity may be in early-stage development, liquidation, or experiencing severe operational disruptions that have resulted in zero cost of revenue and gross profit.
What are the main risks for NUMD?
The company faces an imminent risk of insolvency given that total liabilities ($224.5M) far exceed total assets ($9.4M). Investors are exposed to high volatility and liquidity risk as the firm reports a massive net loss of $68.3 million and zero revenue growth over five years. There is a significant risk of delisting or bankruptcy due to the negative shareholder equity of $215.1 million and inability to cover current liabilities.
What is NUMD's competitive advantage?
As a micro-cap with no current revenue, traditional competitive moats such as market share or brand recognition are not yet established. The company's primary potential advantage lies in its ability to secure future funding for R&D, though the current balance sheet presents significant hurdles to achieving this.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.